An afternoon dose also yielded significantly better overnight (10 p.m. to 4 a.m.) suppression in blood eosinophil counts as a marker of airway inflammation compared with the other two groups, although ...

The possible introduction of tariffs in the U.S. on pharmaceutical imports won't stop Italy's Chiesi Group from supplying patients in need of its products, CEO Giuseppe Accogli told Reuters on ...

A single daily preventer dose of inhaled corticosteroid (beclomethasone), taken mid afternoon, may be the best timing for effective asthma control as it suppresses the usual nocturnal worsening of ...

Family-owned Chiesi, based in the northern Italian city of Parma, provides treatment for rare diseases and respiratory conditions such as asthma and COPD. Sign up here. Chiesi plans to press ahead ...

the company is sponsoring two symposia focused on improving patient quality of life in asthma and COPD and will present during a poster session findings from the TANGO trial, where Chiesi is ...

Asthma is an airway inflammatory disease characterized ... Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD, Menarini, Novartis and Nycomed. The authors have no other relevant affiliations ...

Analysts at Jefferies have previously predicted $1.5 billion in sales at peak for Trelegy, mostly from COPD but with asthma contributing a portion of that total.